Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudine Isaacs

Showing results (1-10 of 329) with videos related to

Pageof 33
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Incorporating neratinib into clinical practice for patients with HER2-positive metastatic breast cancerClaudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Risk of recurrence in early-stage, HER2-positive breast cancerClaudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemopreventionClaudine Isaacs
The Breast Journal|June 29, 2005
Breast cancer-related pseudocirrhosis and esophageal varicesVeena Chandrakar, Claudine Isaacs
Molecular Diagnosis & Therapy|June 16, 2007
Management updates for women with a BRCA1 or BRCA2 mutationRachel Nusbaum, Claudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Treatment of primary breast tumors in de novo metastatic breast cancerTheresa Lee, Claudine Isaacs
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor TestingFilipa Lynce, Claudine Isaacs
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2016
Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime TimeFilipa Lynce, Claudine Isaacs
Oncology (Williston Park, N.Y.)|December 24, 2005
Evaluation and management of women with BRCA1/2 mutationsBeth N Peshkin, Claudine Isaacs
Current Treatment Options in Oncology|February 19, 2005
Utilizing prognostic and predictive factors in breast cancerDeepa S Subramaniam, Claudine Isaacs
Pageof 33

Showing results (1-10 of 329) with videos related to

Sort By:
Pageof 33
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Incorporating neratinib into clinical practice for patients with HER2-positive metastatic breast cancerClaudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Risk of recurrence in early-stage, HER2-positive breast cancerClaudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemopreventionClaudine Isaacs
The Breast Journal|June 29, 2005
Breast cancer-related pseudocirrhosis and esophageal varicesVeena Chandrakar, Claudine Isaacs
Molecular Diagnosis & Therapy|June 16, 2007
Management updates for women with a BRCA1 or BRCA2 mutationRachel Nusbaum, Claudine Isaacs
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Treatment of primary breast tumors in de novo metastatic breast cancerTheresa Lee, Claudine Isaacs
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor TestingFilipa Lynce, Claudine Isaacs
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2016
Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime TimeFilipa Lynce, Claudine Isaacs
Oncology (Williston Park, N.Y.)|December 24, 2005
Evaluation and management of women with BRCA1/2 mutationsBeth N Peshkin, Claudine Isaacs
Current Treatment Options in Oncology|February 19, 2005
Utilizing prognostic and predictive factors in breast cancerDeepa S Subramaniam, Claudine Isaacs
Pageof 33